T1	Treatment 35 46	risedronate
T2	Treatment 562 728	received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low.
T3	Treatment 770 840	the 2.5 mg group was discontinued by protocol amendment after 2 years.
